Stock market indices are down on Tuesday due to further military escalation between Israel and Iran, which in an extreme scenario threatens to increase oil prices and would make it harder to fight inflation, pushing back the prospect of rate cuts by the Federal Reserve. On the other hand, investors are reacting to a sharp decline in US retail sales, which could trigger changes in the Fed earlier than previously expected.
At the time of writing this entry, the Nasdaq index on the cash market is losing 0.47%, the S&P500 0.39%, and the Russell 2000 closes at 0.57%.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
US100 (D1 interval)
The Nasdaq-100 index, represented by the US100 contract, is trading today close to 0.5% lower than yesterday's close. The index continues to maintain a dynamic upward trend, illustrated by exponential moving averages (50-, 100-, and 200-day EMAs, respectively). Moreover, Bollinger Bands show that US100 is currently holding within the statistical range structure of this instrument for the last 14 sessions. From a technical perspective, the 21,000 round zone remains a significant price support, while the historical high near 22,300 points is a resistance.
Source: xStation 5
Corporate News:
Solar stocks are falling in pre-market trading after Senate Republicans released a bill that would end tax breaks for wind and solar energy earlier than for other sources. Enphase Energy, Inc. (ENPH.US), Sunrun (RUN.US) and SolarEdge Technologies (SEDG.US) are down 36%, 20% and 30%, respectively, on Wall Street before the open.
Fastly (FSLY.US) fell 1.9% after the cloud platform provider promoted Chief Product Officer Kip Compton to CEO, replacing Todd Nightingale, who resigned from the company to take a job at Arista Networks (ANET.US).
Eli Lilly (LLY.US) is acquiring Verve Therapeutics (VERV.US), a company developing innovative gene therapies for heart disease, offering shareholders up to $13.50 per share (cash + future distribution rights), sending VERV stock soaring.
- Verve shareholders will receive $10.50 per share in cash at the close of the deal.
- Additionally, each shareholder will receive a so-called contingent value right (CVR), which is the right to a potential additional payment of up to $3.00 per share if the company reaches a specified clinical milestone (the first patient receives VERVE-102 therapy in a Phase 3 study in the US within 10 years of the closing of the transaction).
- The total maximum value of the acquisition is $13.50 per share (or approximately $1.3 billion)
Verve shares are gaining nearly 77% at the beginning of today's session on Wall Street, to just over $11 per share.
Source: xStation
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
